A streak plate for bacteria culture in a lab.

...

Melissa Fleur Afshar

By Melissa Fleur Afshar

Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


Warnings that antimicrobial resistance (AMR) could become a deadlier global threat than cancer were issued at Davos this week, with experts cautioning that the world is heading toward a preventable crisis that is not getting the attention it needs.

Speaking at the Frontiers Science House, Vanina Laurent Ledru, chief public health and government affairs officer of Institut Mérieux and bioMérieux, said AMR is set to become the next pandemic, with the potential to kill more people than cancer by 2050 if governments fail to act.

“One critical point that I am very concerned about is what I call the next pandemic enabled by public mistrust," Ledru said, "and that is the COVID-19 in front of us with antimicrobial resistance. Basically, antimicrobial resistance or drug acquired infections will kill more than cancer by 2050. Is anyone talking about that at Davos? No one is speaking about it.”

Read More on Health

In a press release, Frontiers—the research publisher behind the Science House—added: "“Antimicrobial resistance pandemic will kill more people than cancer by 2050 and no one at Davos is talking about it."

Ledru's comments were echoed by Peter Sands, executive director of The Global Fund to Fight AIDS, Tuberculosis and Malaria, and Adèle James, co‑founder and chief technology officer of Phagos, who amplified Ledru's plea for action and global coordination, warning that AMR could accelerate while the focus of world leaders remains elsewhere.

Ledru's remarks followed the session “the science trust dividend: enabling innovation and adoption,” where speakers raised concerns about declining public trust in data and science. They said this shift is undermining policymaking, which in the case of AMR could lead to a slower implementation of proven solutions and a higher number of a fatalities.

A streak plate for bacteria culture in a lab.

...

“AMR is a pandemic with a probability of 100 percent," Sands said."It is guaranteed to happen. It is already happening. Yet we have failed to mobilize significant resources to mitigate it."

Despite AMR’s projected human toll, speakers noted that the issue has received little public attention during the wider Davos agenda.

James added: “AMR is a major, major problem and some people describe it as a silent pandemic. So, it is great to have the Frontiers Science House space to discuss it in Davos and in the middle of the most important people taking decisions. And it is the first major step to address the problem from the root.”

Participants in the discussion around AMR included Flemming Kondrasen, chief scientific officer of Novo Nordisk Foundation; John Schoonbee, global chief medical officer of Swiss Re; and Steve Clemons, editor at large of the National Interest.

These speakers in particular pointed to possible solutions for the expected pandemic. These include phage‑based medicines—natural predators of bacteria—as a promising option for infections that no longer respond to antibiotics.

However, they warned that new drugs alone cannot solve an AMR crisis, which must be managed over time through policymakers and health systems that emphasize proper nutrition, hygiene practices and everyday behaviors that limit transmission.

The number of new cancer cases is steadily rising, with there expected to be 30.5 million new cases by 2050. With scientists warning that AMR could outpace cancer as a leading cause of death within a generation, experts at Davos said the threat is clear—but worry that without urgent attention, the world may once again wait too long to act.

Do you have a tip on a health story that Newsweek should be covering? Do you have a question about antimicrobial resistance? Let us know via health@newsweek.com.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines